Trials / Completed
CompletedNCT00029523
DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor
A Randomized Clinical Study to Determine the Patient Benefit and Safety of Depocyt (Cytarabine Liposome Injection) for the Treatment of Neoplastic Meningitis
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (planned)
- Sponsor
- Pacira Pharmaceuticals, Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out how well an experimental drug called DepoCyt works for neoplastic meningitis (cancer that has spread to the tissues around the brain and spinal cord). DepoCyt is a new slow-release form of the cancer drug called ara-C (cytarabine). Cytarabine has been used for many years to treat cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Intrathecal (injected into the spinal fluid) DepoCyt | |
| DRUG | Intrathecal methotrexate | |
| DRUG | Intrathecal cytarabine (also known as ara-C) |
Timeline
- Start date
- 2001-04-01
- Completion
- 2004-11-01
- First posted
- 2002-01-16
- Last updated
- 2007-02-28
Locations
23 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00029523. Inclusion in this directory is not an endorsement.